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Chronic granulomatous disease (CGD) is a rare inherited disease of the phagocyte NADPH oxidase system causing
defective production of toxic oxygen metabolites, impaired bacterial and fungal killing, and recurrent life-threatening
infections. We identified a novel gram-negative rod in excised lymph nodes from a patient with CGD. Gram-negative
rods grew on charcoal-yeast extract, but conventional tests could not identify it. The best 50 matches of the 16S rRNA
(using BLAST) were all members of the family Acetobacteraceae, with the closest match being Gluconobacter sacchari.
Patient serum showed specific band recognition in whole lysate immunoblot. We used mouse models of CGD to
determine whether this organism was a genuine CGD pathogen. Intraperitoneal injection of gp91
phox  / (X-linked) and
p47
phox  / (autosomal recessive) mice with this bacterium led to larger burdens of organism recovered from knockout
compared with wild-type mice. Knockout mouse lymph nodes had histopathology that was similar to that seen in our
patient. We recovered organisms with 16S rRNA sequence identical to the patient’s original isolate from the infected
mice. We identified a novel gram-negative rod from a patient with CGD. To confirm its pathogenicity, we demonstrated
specific immune reaction by high titer antibody, showed that it was able to cause similar disease when introduced into
CGD, but not wild-type mice, and we recovered the same organism from pathologic lesions in these mice. Therefore,
we have fulfilled Koch’s postulates for a new pathogen. This is the first reported case of invasive human disease caused
by any of the Acetobacteraceae. Polyphasic taxonomic analysis shows this organism to be a new genus and species for
which we propose the name Granulobacter bethesdensis.
Citation: Greenberg DE, Ding L, Zelazny AM, Stock F, Wong A, et al. (2006) A novel bacterium associated with lymphadenitis in a patient with chronic granulomatous disease.
PLoS Pathog 2(4): e28. DOI: 10.1371/journal.ppat.0020028
Introduction
Chronic granulomatous disease (CGD) is a rare inherited
disease of the phagocyte NADPH oxidase system that leads to
defective production of toxic oxygen metabolites and
impaired killing of certain microbes [1]. Clinically, patients
develop recurrent life-threatening infections with catalase-
producing organisms as well as tissue granuloma formation
[2]. The bacteria and fungi that commonly cause infection in
CGD include: Staphylococcus aureus, Serratia marcescens, Burkhol-
deria cepacia, Nocardia and Aspergillus species [3–7]. Rare
infections with organisms only encountered in CGD, such
as Paecilomyces sp. and Trichosporon inkin, suggest that patients
with CGD have a unique susceptibility pattern [1]. However,
when a speciﬁc microbiologic diagnosis cannot be made,
patients are frequently treated with broad-spectrum anti-
microbials that cover the most likely pathogens.
In the course of evaluation of fever and lymphadenitis in a
patient with CGD, we identiﬁed a novel gram-negative rod.
This organism belongs to a family of bacteria that has not
been reported to cause invasive human disease. To prove that
this organism was the cause of this patient’s clinical
syndrome, we utilized classical methods ﬁrst described by
Robert Koch in the late 19th century [8], supplemented with
modern immunologic and genetic approaches. When faced
with new potential pathogens, there remain situations in
which Koch’s postulates are as necessary to understand the
etiology of infections as they were over a hundred years ago.
Case Report
The patient was a 39-year-old man with X-linked chronic
granulomatous disease (CGD) complicated by multiple
episodes of S. aureus pneumonia and Aspergillus pneumonia,
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drainage. He had remained healthy on trimethoprim-sulfa-
methoxazole alone for many years. In April 2003 he was
hospitalized for fever and chills after returning from a trip to
the Bahamas. Blood and urine cultures, cytomegalovirus
serologies, cryptococcal antigen, and a transthoracic echo-
cardiogram were not diagnostic. He had evidence of remote
Epstein-Barr virus infection. A computed tomography scan of
his chest showed new necrotic subcarinal and right hilar
lymph nodes and two calciﬁed granulomata in the right lower
lobe. Inpatient intravenous vancomycin, ceftazidime, and
voriconazole followed by outpatient oral voriconazole and
trimethoprim-sulfamethoxazole were not curative. One
month later, while on his outpatient regimen, repeat blood,
sputum, and urine cultures were again negative. Cerebrospi-
nal ﬂuid examination was unremarkable. Gallium and Indium
scans showed increased uptake in the right cervical and
anterior mediastinal lymph nodes. Mediastinoscopy with
biopsy of carinal lymph nodes showed caseating granulom-
atous inﬂammation. Calcoﬂuor white, AFB (acid-fast bacillus),
and gram stains were negative as were fungal and bacterial
cultures. In addition, AFB cultures were negative after eight
weeks. Because of three months of fever, chills, and 10-lb
weight loss despite empiric therapy, the patient was referred
to the National Institutes of Health.
MRI of the chest showed mediastinal lymphadenopathy in
the precarinal, subcarinal, and hilar regions with extensive
necrosis (in Figure 1, see Figure 1A). Fevers, chills, fatigue,
and night sweats persisted despite addition of azithromycin
and moxiﬂoxacin. Five months after symptom onset, he
developed new painful left supraclavicular lymphadenopathy.
Given the lack of response to empiric antimicrobials and the
lack of microbiologic diagnosis, four involved left cervical
and supraclavicular lymph nodes were removed. Pathology
showed extensive necrotizing pyogranulomatous lymphade-
nitis with microabscess formation (Figure 1B and 1D). Fungal,
gram, and AFB stains on sectioned lymph nodes were
negative. A Warthin-Starry stain showed scant coccobacillary
forms (Figure 1C). A novel gram-negative rod grew from
three lymph node cultures on buffered charcoal yeast extract
agar plates after four days of incubation.
The patient was initially treated in the fall of 2003 with
doxycycline, meropenem, and a steroid taper. His remaining
lymph nodes decreased in size over subsequent months.
However, fever and enlarging lymphadenopathy returned in
the fall of 2004. Since that time, he has required cervical
lymph node excisions on four separate occasions. In May,
June, and November of 2005, this new organism was again
cultured from excised lymph nodes.
Results
Gram-negative rods were isolated from three of the four
cervical lymph node cultures, on buffered charcoal yeast
extract plates (Remel, Lenexa, Kansas, United States) after
four days incubation at 35 8C. The organism was a non-motile
coccobacillus that was catalase-positive and oxidase-negative.
Lysine and ornithine decarboxylases and arginine dihydro-
lase all were negative. Urease was positive; there was weak
fermentation of glucose, and there was no acid production
from lactose, mannitol, sucrose, maltose, or xylose. These
results were conﬁrmed at the Centers for Disease Control and
Prevention (L. Helsel, personal communication). The API 20
NE (BioMerieux, Durham, North Carolina, United States) and
RapID NH (Remel) commercial kits generated codes 0200000
and 1501, respectively, neither of which yielded an identi-
ﬁcation.
In view of the failure of conventional tests to identify the
organism and its fastidious growth characteristics, we
sequenced the 16S rRNA gene and searched for related
sequences in GenBank. The best 50 matches by BLAST search
were all members of the family Acetobacteraceae, with the
closest match being Gluconacetobacter sacchari (95.7% similar-
ity) and Gluconacetobacter liquefaciens (95.5% similarity). The
isolate from May of 2005 also had 16S sequencing performed
and was identical to the original isolate. The 16S rDNA
sequence similarity between the patient isolate and other
commonly encountered pathogenic gram-negative rods was
very low (;80%) (Figure 2).
Initial attempts to perform antibiotic susceptibility testing
by microdilution and by a disk susceptibility test failed due to
poor growth in broth and on Mueller-Hinton agar, respec-
tively. Therefore, susceptibility testing was done on tryptic
soy agar (TSA) sheep blood agar plates by the E-test.
Minimum inhibitory concentrations (MICs) read after 48 h
and 96 h of incubation at 35 8C showed the following results:
ciproﬂoxacin (MIC . 32), azithromycin (MIC . 256),
cefepime (MIC . 256), ceftriaxone (MIC ¼ 16), meropenem
(MIC . 32), and chloramphenicol (MIC . 256); amikacin
showed an MIC¼32. At 48 h incubation, doxycycline showed
MIC ¼16 and trimethoprim-sulfamethoxazole showed MIC ¼
0.38; however, at 96 h of incubation, resistance to both drugs
was observed.
The isolation of a previously unknown gram-negative rod
from a patient with a rare immune disorder does not
immediately prove causality. Contamination can occur
during surgery or in the laboratory. To conﬁrm the biological
relevance of the isolated organism to our patient, we sought
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Synopsis
As new bacteria continue to be discovered every year, it is inevitable
that some of them will be found to cause human disease. The
authors describe the isolation and characterization of a new
bacterium, grown from a patient with chronic granulomatous
disease (CGD). In this genetic disease, one of the main lines of
defense against infection, the neutrophil, has a discrete defect in the
generation of superoxide, leading to recurrent infections with a
narrow spectrum of bacteria and fungi. This new organism was
cultured from lymph nodes that had been inflamed for several
months. To prove that this new bacterium was indeed a pathogen,
Greenberg and colleagues measured specific antibody response in
the patient: they inoculated CGD mice with this organism and
reproduced the appearance of the human infection; they recovered
the organism in pure growth from infected mouse spleens.
This new bacterium belongs to the family Acetobacteraceae,
bacteria that are found widely in the environment. They have a
variety of industrial uses, such as the production of vinegar, but
have never been reported to cause invasive human disease. Disease-
causing organisms remain to be discovered. The researchers outline
some of the steps that can be taken to verify the pathogenicity of
novel organisms.to determine whether this organism was immunologically and
immunopathologically linked to his disease.
To prove that this organism stimulated an immune
response in our patient, whole bacterial lysates were exposed
to unfractionated patient plasma in an immunoblot. Four
distinct bands were seen at approximately 38 kDa, 45 kDa, 47
kDa, and 62 kDa. To conﬁrm unique band recognition,
neither related organisms (Acetobacter estunensis, Gluconaceto-
bacter xylinus) nor unrelated organisms (E. coli, Proteus mirabilis)
showed similar band patterns when incubated with the
patient’s serum (Figure 3A). In addition, sera stored from
the patient years prior to the onset of his symptoms showed
no reactivity on immunoblot (courtesy of Dr. Mary Dinauer,
Figure 3B). To further characterize the recognized bands,
two-dimensional gels of bacterial protein extracts were
performed. Proteins detected with patient plasma by immu-
noblot were subjected to peptide mass ﬁngerprinting
(unpublished data). To further identify antigens being
recognized on the two-dimensional gel immunoblots, protein
extracts were run over a column coated with puriﬁed patient
IgG. These two methods identiﬁed at least one of the proteins
as a methanol dehydrogenase (69 kDa; EC 1.1.99.8). The
recent completion of the genome sequence of this novel
organism allowed us to speciﬁcally match this recognized
peptide to this organism. The amino acid sequence of the
recognized methanol dehydrogenase is shown in Figure 4.
Studies to identify the other immunoreactive peptides are
under way. Unique immunoblot protein recognition contin-
ues to be evident at dilutions of patient plasma of 1:100,000.
Of interest, immunoblot patterns similar to those of this
patient against this novel organism have been found in 3/19
patients with CGD and in 1/20 healthy individuals tested,
respectively.
In addition to immunoblots, scanning immunoelectron
microscopy and immunotransmission electron microscopy
were performed. Immunotransmission electron microscopy
images were taken after incubating colonies with either
patient or normal plasma followed by gold-labeled anti-
human IgG. Whereas bacteria incubated with plasma from
normal humans failed to label with colloidal gold, those
probed with plasma from the patient were clearly decorated
with gold particles (Figure 5).
Having conﬁrmed that the patient had an immune response
to the cultured organism, we sought to determine whether it
showed pathogenicity in CGD. We used mouse models of CGD
to determine whether this organism caused infection in the
setting of CGD, and, if so, was it pathologically similar to that
seen in our patient. gp91
phox /  (X-linked) and p47
phox / 
(autosomal recessive) mice were injected with various
amounts of organisms (10
2 to 10
8 CFU) i.p. and then organs
and lymph nodes were harvested for culture and pathology at
different time points. gp91
phox /  and p47
phox /  mice yielded
histopathology similar to that seen in our patient’s lymph
nodes (Figure 6). In contrast, wild-type mice did not develop
pyogranulomatous abscesses in the lung or lymph nodes,
although a few demonstrated lymphoid hyperplasia. Spleno-
megaly was noted in both wild-type and CGD mice injected
with the organism, but to a greater degree in the knockout
mice. At all time points examined, organism recovery from
spleen homogenates was greater in the CGD mice compared
Figure 1. Clinical and Pathological Images of the Patient’s Lymph Nodes
(A) MRI of the chest showing adenopathy in the precarinal, subcarinal, and hilar regions. Central areas of diminished enhancement suggest necrosis
(arrow).
(B) Removed cervical lymph node showing necrotizing granulomatous lymphadenitis with abscess formation (pyogranuloma).
(C) Warthin-Starry stain of the cervical lymph node (magnification 6003) showing coccobacillary organisms.
(D) Higher magnification H&E of a necrotizing granuloma. There is an area of neutrophils and cellular debris on the right, bounded by a poorly defined
layer of palisaded epithelioid histiocytes. Outside this layer is a mix of lymphocytes and histiocytes.
DOI: 10.1371/journal.ppat.0020028.g001
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A Novel Pathogenwith wild-type mice. When 10
7 CFU of bacteria were injected
i.p. into ten wild-type and ten gp91
phox /  mice, nine days
post-inoculation the mean CFU/spleen in the wild-type mice
was 11,550 compared with 41,720 in the gp91
phox /  mice
(Figure 7) (p , .001; two-tailed t-test). Gram stains, growth
characteristics, and speciﬁc antibody recognition of the
bacteria isolated from organ homogenates were similar to
those of the patient’s original culture. To prove that the
pathologic organism recovered from the animals was the
same as the one isolated from the patient, the 16S sequence
was determined and was identical to the original isolate.
To determine if the pathology observed in CGD mice was
unique to this new organism, or whether other members of
the Acetobacteraceae could cause a similar disease, we
injected six CGD and four wild-type mice with this new
organism (10
7 CFU) and another six CGD and ﬁve wild-type
mice with another member of the Acetobacteraceae family, G.
oxydans (ATCC 621H). Mice were sacriﬁced at nine days. All
the mice, both wild-type and CGD, injected with the new
bacterium showed pathologic changes in the lymph nodes
ranging from moderate hyperplasia to the presence of
plasmacytosis, atypical macrophages and lymphadenitis,
although the changes in the wild-type mice were compara-
tively mild. In contrast, only 2/6 CGD mice and 2/5 wild-type
mice injected with G. oxydans showed any pathologic changes,
and these were limited to mild lymphoid hyperplasia and
plasmacytosis. When taken together, the new bacterium
caused more severe pathology when compared with another
member of the Acetobacteraceae.
Discussion
When we had identiﬁed a novel gram-negative rod from a
CGD patient with fever and lymphadenitis, our ﬁrst concern
was to determine whether this organism was truly associated
with his clinical syndrome. This question is critically
important, insofar as this is a previously unrecognized
organism without a body of literature to inform us as to its
frequency or behavior.
Given that we have an animal model for CGD, we were able
to utilize rules that were developed by Koch over one hundred
years ago as he was trying to prove the etiology of tuber-
culosis. Although Koch’s postulates cannot be applied in every
situation, they are invaluable in the proof of causality. The
isolation of this organism from our patient’s diseased lymph
nodes, its ability to cause similar disease when introduced into
mouse models of CGD, the ability to isolate the same organism
from these mice, and redemonstration of its identity prove
that this novel bacterium in fact caused disease in our patient.
In addition to using an animal model to conﬁrm
pathogenicity of this organism in CGD, further evidence of
its having infected this patient was demonstrated by his
seroconversion from negative to high titer antibody. Screen-
ing of plasmas from other patients with CGD and people
without it suggests that the bands at 38 kDa and 62 kDa may
be characteristic of the human response to this organism. The
recently completed genome sequence of this organism will
prove valuable in determining the immunoreactive bands
Figure 3. Immune Response to G. bethesdensis
(A) An immunoblot showing the patient’s plasma incubated with whole
bacterial protein extracts of this new pathogen and other organisms as
indicated (2 lg total protein per lane). Patient plasma was used at a
1:1000 dilution.
(B) Patient’s plasma from 1999 (a) and 2003 (b) incubated with whole
bacterial protein extracts.
DOI: 10.1371/journal.ppat.0020028.g003 Figure 2. Novel Bacterium Groups in the Family Acetobacteraceae
(A) Phylogenetic tree derived from the 16S rDNA sequence of the patient
isolate, two Gluconacetobacter spp, two Acetobacter spp., and other
gram-negative rods associated with CGD (S. marcescens, B. cepacia) and
not associated with CGD (Escherichia coli). This unrooted radial tree
shows the patient isolate emerging as an independent branch that
clustered together with members of the family Acetobacteraceae. The
scale bar represents the number of substitutions per site.
(B) Percentage of similarity of 16S rDNA sequences of the patient isolate,
two Gluconacetobacter spp., two Acetobacter spp., and the gram-
negative rods shown in (A).
DOI: 10.1371/journal.ppat.0020028.g002
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A Novel Pathogenthat are speciﬁc for this bacterium. When infected, both CGD
and wild-type mice develop antibody. However, only CGD
mice recapitulate the human immunopathology, conﬁrming
that this is a genuine pathogen in CGD.
This novel bacterium caused fever, lymphadenitis, and
weight loss over almost six months in a patient with X-linked
CGD, but was not fatal. Even at inocula as high as 10
8, there
were no deaths among the mice used in our challenge studies.
We followed animals up to four months after infection; all
mice cleared the infection spontaneously over time, as
indicated by decreasing colony counts from organ homoge-
nates. Interestingly, although pathologic changes were seen in
the infected CGD mice, a few of the normal mice had low-
level positive cultures from spleen homogenates for up to 76
days. Both CGD and normal mice produced antibody, as did
our patient. The repeated isolations of this organism from
our patient suggest that antibody production alone is not
protective. It remains unclear whether the repeated isolation
of this bacterium from our patient’s diseased lymph nodes
represents relapse or reinfection from as yet unidentiﬁed
environmental reservoir(s). In either case, given its apparent
low virulence, further investigation of this organism may shed
light on the mechanisms of microbial killing in CGD.
Comparing the genome of this organism to other available
genomes of CGD pathogens may provide insight into
common virulence properties.
Since the initial acceptance of this manuscript, we have
isolated Granulobacter bethesdensis from two more individuals
with CGD who presented with similar clinical syndromes. G.
bethesdensis was conﬁrmed with similar biochemical and
molecular techniques, and the isolates were shown to be
molecularly distinct.
These are the ﬁrst reported cases of invasive human disease
caused by any of the Acetobacteraceae. The family Aceto-
bacteraceae comprises several genera including the genus
Gluconacetobacter and Acetobacter. The closest 16S rRNA gene
sequence match was to G. sacchari at 95.7%. However, strains
that have a 16S rDNA sequence similarity below 97% are not
considered the same species [9]. The sequence similarity of
two species of Gluconacetobacter and two species of Acetobacter
are shown in Figure 2. A polyphasic taxonomic approach
shows that this organism belongs to a new genus and species
in this family (unpublished data). Members of the genera
Gluconacetobacter, Acetobacter, Gluconobacter, and Acidomonas [10]
have been called the acetic acid bacteria, because they derive
energy from the aerobic oxidation of ethanol to acetic acid.
They have been cultured from fruits, fermented foods, plants,
soil, and water [11–14], are utilized industrially in the
production of vinegar, and are encountered during the
fermentation of wine [15–18]. Given that this novel pathogen
was isolated from a patient with CGD at the National
Institutes of Health, we propose the name Granulobacter
bethesdensis.
Patients with CGD are susceptible to infections caused by
catalase-producing organisms. It is thought that organisms
that produce catalase scavenge their own hydrogen peroxide
and thus deprive the CGD phagocyte of the opportunity to
use oxidative metabolites against it [1]. However, many
organisms are catalase-positive and do not cause disease in
CGD. In fact, the list of catalase-positive organisms that cause
disease in CGD is quite narrow. This suggests that there are
mechanisms beyond catalase that confer pathogenicity upon
organisms that infect patients with CGD. It is hoped that the
addition of a new organism to the CGD-speciﬁc infection list
will allow further characterization of these virulence path-
ways. Many questions remain regarding the clinical epidemi-
Figure 4. The Amino Acid Sequence of the Methanol Dehydrogenase
Methanol dehydrogenase (69 kDa; EC 1.1.99.8) was identified as one of the peptides recognized by the patient plasma. Amino acids in red represent
sequences that were matched during peptide mass fingerprinting.
DOI: 10.1371/journal.ppat.0020028.g004
Figure 5. Immune Electron Microscopy of the New Bacterium
Bacteria were adsorbed to Parlodion-coated grids and then probed with
either normal plasma (A) or plasma from the CGD patient (B), labeled
with anti-human IgG/colloidal gold, and negatively stained with uranyl
acetate.
DOI: 10.1371/journal.ppat.0020028.g005
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A Novel Pathogenology of this newly identiﬁed organism, such as its environ-
mental reservoir and its seroprevalence in other disease
states. Given that the Acetobacteraceae are ubiquitous
environmental organisms, it is striking that they have never
been reported to cause invasive disease, although a case of
peritonitis associated with Asaia bogorensis in a patient with a
peritoneal dialysis catheter has been recently reported [19].
The difﬁculty in culturing this organism from pathologic
specimens, and the apparent seropositivity even among
healthy people, suggest that there have been other encounters
with this organism that have not been found previously. The
clinical manifestations of this pathogen in other patients with
CGD, and potentially in patients without CGD, are important
subjects for future investigation.
Materials and Methods
Microbiology. The growth of the isolate was assessed on various
media under different incubation conditions. The organism grew
best at 358C on Acetobacter Medium [20] with the following
modiﬁcations: glucose (50.0 g/L), CaCO3 (12.5 g/L), autolyzed yeast
(5.0 g/L), agar (15.0 g/L). Colonies growing on this modiﬁed
Acetobacter Medium developed a yellow color after 5 days. Good
growth after 4–5 days of incubation was also obtained on buffered
charcoal yeast extract agar and on TSA with sheep blood (Remel).
Growth was not improved in a CO2 atmosphere.
Commercial biochemical kits, supplementary phenotypic tests, and
sequencing were used to identify the isolate. Commercial kits used
included the API 20 NE (BioMerieux) and the RapID NH (Remel).
Additional phenotypic tests included oxidase, catalase, oxidative-
fermentative medium with different sugars (OF medium King,
Remel), lysine and ornithine decarboxylases, arginine dihydrolase,
urease test (Rapid Urea Slant, Hardy Diagnostics, Santa Maria,
California, United States), and motility. Susceptibility testing was
performed on TSA with sheep blood by the E-test (Amersham
Biosciences Biodisk, Piscataway, New Jersey, United States).
Sequencing and phylogenetic analysis. The full 16S rRNA gene was
Figure 7. Graph Showing Organism Recovery from Spleen Homogenates
at Nine Days Post-Inoculation
The — mark shows the mean value. Mean CFU/spleen in the wild-type
mice was 11,550, compared with 41,720 in the knockout animals (p ,
.001; two-tailed t-test).
DOI: 10.1371/journal.ppat.0020028.g007
Figure 6. Histopathology of Mouse Lymph Nodes
(A) Normal lymph node architecture of a gp91
phox /  uninjected control mouse (magnification 53).
(B) Normal lymph node architecture of a gp91
phox /  mouse after 10
7 i.p. inoculation of Gluconobacter oxydans (magnification 53).
(C) Moderate lymphoid hyperplasia and presence of atypical macrophages in the lymph node of a gp91
phox /  mouse after 10
6 intraperitoneal
inoculation of the novel organism (magnification 53).
(D) View of the epithelioid macrophages in the lymph node at 403.
(E) Lymphadenitis in the cervical lymph node of a gp91
phox /  mouse after 10
7 i.p. inoculation of the novel organism (magnification 53).
(F) View of the pyogranulomatous reaction in the lymph node at 203.
(A,B,E,F) are from mice that were sacrificed at nine days post-inoculation. (C and D) are from a mouse that was sacrificed at 76 days post-inoculation.
DOI: 10.1371/journal.ppat.0020028.g006
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A Novel Pathogensequenced using the MicroSeq Full Gene 16S rRNA Bacterial
Isolation Sequencing Kit (Applied Biosystems, Foster City, California,
United States), according to the manufacturer’s protocol, and
sequences were analyzed using the 3100 Genetic Analyzer (Applied
Biosystems). The Lasergene program (version 5.51; DNASTAR,
Madison, Wisconsin, United States) was used for sequence assembly
and alignment. The assembled 16S rDNA sequence from the patient
isolate was compared with 16S rDNA sequences available in GenBank
databases using the standard nucleotide–nucleotide basic local
alignment search tool (BLASTn) program (National Center for
Biotechnology Information, Bethesda, Maryland, United States).
Multiple sequence alignments of the 16S rRNA gene sequences from
the isolate and the closest GenBank matches were done by the
CLUSTAL W method.
Phylogenetic analyses were performed with the PHYLIP version
3.5c package [21]. Distance matrices based on Kimura’s two-
parameter model were produced with DNADIST program, and a
neighbor-joining tree constructed with the NEIGHBOR program.
The resulting unrooted tree was depicted using the TreeView version
1.4 package [22].
Immunology studies: Preparation of protein extracts, SDS gel
electrophoresis, and immunoblot analysis. Bacterial cells were
pelleted by centrifugation and extracted with the Pierce (Rockford,
Illinois, United States) bacterial protein extraction reagent. Protein
concentrations were determined using the Pierce protein assay. 2lg
of total protein per lane were electrophoresed on 10% SDS–PAGE,
and the separated proteins transferred to PVDF membrane (Invi-
trogen Life Technologies, Carlsbad, California, United States). The
membrane was blocked in TBS buffer containing 5% nonfat dried
milk and 0.05% Tween-20 before incubation with human or mouse
serum (1:100 to 1:100,000 dilution). After three washes, the
membrane was incubated with horseradish peroxidase conjugated
goat anti-human or goat anti-mouse IgG (1:10000 to 1:20000;
Amersham Biosciences, Little Chalfont, United Kingdom). The blots
were developed using the enhanced chemiluminescence kit (ECL
Plus, Amersham Biosciences) as described by the manufacturer.
Challenge studies: Mice. C57BL/6 wild-type (Jackson Lab, Bar
Harbor, Maine, United States) and gp91




National Institute of Allergy and Infectious Diseases animal facility
under speciﬁc pathogen-free conditions. All experiments were
approved by the Institute’s Animal Care and Use Committee. Mice
were 4–8 mo old and sex-matched for each set of experiments.
Mouse infection and sample collection. The organism propagated
from the patient’s cervical lymph node cultures served as the source
of the bacteria used in the mouse challenge studies. For these
challenge studies, bacterial colonies growing on TSA with sheep
blood were used to inoculate trypticase soy broth which was
incubated for 10–14 days at 37 8C with 5% CO2. Bacteria were
harvested by centrifugation and the bacterial pellet was washed twice
in Hanks’ balanced salt solution. Bacterial density was determined
spectrophotometrically at 650 nm. Concentrations of bacteria from 2
3 10
8 to 7 3 10
8 CFU were serially diluted in Hanks’ balanced salt
solution and used to infect mice, and simultaneously plated on
trypticase soy agar þ 5% sheep blood plates (Remel) to quantify the
inoculum. Mice were injected i.p. with 0.1 ml diluted bacteria. At 2, 9,
20, 76, and 126 days after challenge, blood was collected either retro-
orbitally or from the tail into sterile tubes for culture and serum
separation. Mice were then sacriﬁced by CO2 asphyxiation. Spleens
and selected lungs were homogenized in 0.5 ml PBS. In one of the
mouse experiments, spleens were homogenized in an amount of PBS
proportional to the spleen’s weight, so CFU/spleen could be
determined. Samples of blood, spleen, or lung homogenates were
serially diluted and inoculated in duplicate onto TSA with 5% sheep
blood plates and incubated at 37 8C with 5% CO2 for 96–120 h, and
colonies were enumerated. For histopathologic analysis, 3 ml of 10%
phosphate-buffered formalin was injected into each lung; the inﬂated
lungs and speciﬁed lymph nodes (cervical, axillary, and inguinal) were




GenBank (http://www.ncbi.nlm.nih.gov/Genbank) accession numbers
are: 16S rDNA sequence from the novel gram-negative rod G.
bethesdensis (AY7889500); G. liquefaciens (X75617); and G. sacchari
(AF127412).
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